UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer

International Journal of Clinical Oncology

Volumn 21, Issue 4, 2016, Pages 696-703

  Miyata, Yoshinori ^a   Touyama, Tetsuo ^b   Kusumi, Takaya ^c   Morita, Yoshitaka ^d   Mizunuma, Nobuyuki ^e   Taniguchi, Fumihiro ^f   Manabe, Mitsuaki ^g  

^a Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^b Nakagami Hospital   (Japan)

^c Keiyukai Sapporo Hospital   (Japan)

^d Graduate School of Health Sciences   (Japan)

^e CANCER INSTITUTE HOSPITAL   (Japan)

^f KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^g YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

Colorectal; Irinotecan; Neutropenia; Polymorphism; UGT1A1 enzyme

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 28; GLYCOSYLTRANSFERASE; IRINOTECAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT HISTORY OF CHEMOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; UNSPECIFIED SIDE EFFECT; ADULT; AGE; ANALOGS AND DERIVATIVES; BODY FLUID; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; GENETICS; HETEROZYGOTE; HOMOZYGOTE; MIDDLE AGED; RISK FACTOR; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; BODY FLUIDS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEUTROPENIA; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84951957539     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0937-x     Document Type: Article

References (20)

1. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047
2. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237
3. Kono A, Hara Y (1991) Conversion of CPT-11 into SN-38 in human tissues. Gan To Kagaku Ryoho 18:2175–2178 (in Japanese)
4. Kawato Y, Aonuma M, Matsumoto K et al (1991) Production of SN-38, a main metabolite of the camptothecin derivative CPT-11, and its species and tissue specificities. Drug Metab Pharmacokinet 6:899–907 (in Japanese)
5. Rivory LP, Robert J (1995) Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36:176–179
6. Haaz MC, Rivory L, Jantet S et al (1997) Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol 80:91–96
7. Ando Y, Saka H, Ando M et al (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921–6926
8. Innocenti F, Undevia SD, Iyer L et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382–1388
9. Minami H, Sai K, Saeki M et al (2007) Irinotecan pharmacokinetics ⁄ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 17:497–504
10. Saito Y, Maekawa K, Ozawa S et al (2007) Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in East Asians and their comparison with other ethnic populations. Curr Pharmacogenom 5:49–78
11. Satoh T, Ura T, Yamada Y et al (2011) Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and ⁄ or UGT1A1*6 polymorphisms. Cancer Sci 102:1868–1873
12. Sai K, Saeki M, Saito Y et al (2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75:501–515
13. Okuyama Y, Hazama S, Nozawa H et al (2011) Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1*28/*6 polymorphisms. Jpn J Clin Oncol 41:477–482
14. Hoskins JM, Goldberg RM, Qu P et al (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99:1290–1295
15. Hu ZY, Yu Q, Pei Q et al (2010) Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res 16:3832–3842. doi:10.1158/1078-0432.CCR-10-1122
16. Hazama S, Nagashima A, Kondo H et al (2010) Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1* 28 polymorphism. Cancer Sci 101:722–727. doi:10.1111/j.1349-7006.2009.01428.x
17. Yamamoto N, Takahashi T, Kunikane H et al (2009) Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non–small cell lung cancer treated with irinotecan. Clin Pharmacol Ther 85:149–154. doi:10.1038/clpt.2008.152
18. Fuchs CS, Moore MR, Harker G et al (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807–814
19. Shiozawa T, Tadokoro J, Fujiki T et al (2013) Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. Jpn J Clin Oncol 43:483–491. doi:10.1093/jjco/hyt040
20. Araki K, Fujita K, Ando Y et al (2006) Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97:1255–1259